Skip to content
Search
YieldTimes

Markets, read closely

Earnings

Earnings update: Purple Biotech reports GAAP loss; Viking Holdings posts non-GAAP miss

Purple Biotech showed a negative GAAP result while Viking Holdings reported weaker-than-expected non-GAAP earnings and revenue.

YieldTimes Markets Desk 1 min read

Stock market trading screens, investor desk with financial reports, corporate earnings press conference
Photo: AlphaTradeZone / Pexels

Lede

Purple Biotech reported a GAAP earnings per share (EPS) loss of -$0.51, while Viking Holdings Ltd posted a non-GAAP EPS of $1.11 that missed by $0.15 and revenue of $2.18 billion that missed by $30 million.

Context

These results add to the ongoing flow of quarterly earnings updates that investors use to gauge company performance and near-term fundamentals.

For Purple Biotech, the reported GAAP EPS of -$0.51 indicates the company recorded a net loss on a generally accepted accounting basis during the reporting period. GAAP figures are typically the headline metric investors compare across companies because they reflect a standardised approach to revenue recognition and expense classification.

Viking Holdings’ update, meanwhile, focuses on non-GAAP performance. The company reported non-GAAP EPS of $1.11, which fell short of expectations by $0.15. It also reported revenue of $2.18 billion, missing $30 million versus expectations. Non-GAAP measures are often used by companies to show performance excluding certain items they consider not reflective of core operations; however, when non-GAAP EPS and revenue both come in below expectations, markets frequently scrutinise underlying demand, pricing and cost control.

With both companies showing shortfalls versus expectations on key metrics—GAAP loss for Purple Biotech and an earnings plus revenue miss for Viking Holdings—the common theme is heightened sensitivity to profitability and sales momentum. The implications can be broader for their respective segments depending on how investors interpret the earnings outcomes relative to guidance and operational trends, though no outlook details were provided in the reported figures.

What to watch

  • Whether management commentary (if any) explains the GAAP loss at Purple Biotech and the drivers behind Viking Holdings’ revenue shortfall.
  • Any reconciliation between Viking Holdings’ non-GAAP and GAAP results, particularly what was excluded to arrive at the non-GAAP EPS figure.
  • Follow-on updates for both companies as investors assess how the results may affect future financial targets.

For information only, not financial advice. This article reports market news and does not recommend buying or selling any security. See the disclaimer.

More from Earnings

All →